



CLX Investment Company, Inc.

(OTC BB: CLXN)

29970 Technology Drive, Suite 203, Murrieta, CA 92563

Telephone: (951) 677-6735 / Facsimile: (951) 677-6573

investors@clxinvestments.com

www.clxinvestments.com

December 2007 Newsletter

CLX Investment Company Solidifies Key Consulting Relationships in the Medical Product Supply Industry

American Health Partners and Safis Solutions Contracted to Provide Services for Current and Future Subsidiary Medical Testing Technologies

CLX Investment Company (stock symbol - OTC BB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, has announced a professional services agreement with American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing products in CLX's subsidiary operations. The first product for which CLX is expected to utilize AHP's market readiness process and distribution management system is Zonda's rapid point of care test for Chlamydia.

The professional services agreement outlines the services that AHP is expected to provide, including preliminary market validation for product efficacy, establishment of clinical trials protocol to meet the appropriate

regulatory requirements, completion of clinical trials, assistance with targeted regulatory approvals for distribution of products within the United States, a market readiness audit, a manufacturing plan, a marketing plan, and a distribution plan to include the identification of and a contract with "1st Choice" distributors.

AHP (www.ahpartners.com) has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States.

With its recent acquisition of a majority percentage of Zonda, CLX's business strategy is focused on the acquisition of innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States. Zonda's medical diagnostic tests, which are based upon enzymatic detection technology, are expected to be just one area of focus for CLX, and management is seeking additional innovative products as potential acquisitions. To that end, CEO Vera Leonard traveled to Dusseldorf, Germany to attend at MEDICA, the world's largest medical trade fair, which was held from November 14-17.

(continued on page 3)

Inside This Issue

CLX Management Attends 2007 MEDICA Trade Event in Germany

Page 2

CEO Greeting - Vera Leonard Addresses New Contracting Relationships

Page 3

About the Company

CLX Investment Company, Inc. (OTC BB: CLXN) is a holding company seeking to provide long-term value for its shareholders by executing an acquisition strategy in the medical diagnostic testing field.

CLX owns a 51% equity interest in Zonda, Incorporated (www.zondaincusa.com), a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets. The Company has announced an agreement to acquire the remaining 49% of Zonda and plans to make this subsidiary a significant focus of CLX's operations.

CLX also holds a common stock position in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded company that designs, develops, and manufactures vividly illuminated motion billboards.



CLX Investment Company Announces Successful Attendance at MEDICA 2007, 39th World Forum for Medicine International Trade Fair

Meetings With Current Distributors and Identification of New Potential Acquisition Candidates Result From the Show

CLX has reported that CEO Vera Leonard and other company representatives have successfully completed their attendance at MEDICA, the world's largest medical trade fair, which was held November 14-17, 2007 in Dusseldorf, Germany.

The MEDICA trade fair, titled the 39th World Forum for Medicine (www.medica.de), featured the latest medical product developments from around the world, and Ms. Leonard was seeking to identify quality medical testing technologies as potential acquisitions for CLX. The 2007 MEDICA event attracted over 4,300 exhibitors from approximately 100 countries around the world.



One purpose of CLX's visit to MEDICA was for Ms. Leonard and Zonda's Director of European Sales, Mr. Pavel Holik, to meet with Zonda's current European distributors. This was the first opportunity for Ms. Leonard, who also serves as CEO of Zonda, to meet face to face with Zonda's European distributors.

Zonda's first medical test, for Chlamydia, is currently sold throughout Europe under the HandiLab brand, and a U.S. launch is being planned.

"I was pleased to find that the current distributors of Zonda's products in Europe were very happy with the product, and I felt that the face to face meetings were extremely beneficial and bode well for the long-term potential of these relationships," stated Ms. Leonard.

Beyond the meetings with Zonda distributors, Ms. Leonard attended MEDICA to identify additional innovative products as potential acquisitions and opportunities for distribution relationships for CLX.

(continued on page 3)

Greetings from the CEO

I am pleased to have this opportunity to address CLX shareholders, especially so soon after my recent trip to Germany for the MEDICA trade fair. This event is truly where the worldwide medical product community gathers, and I was extremely pleased to report positive developments on multiple fronts as a result of the trip.



First, as we reported in our MEDICA follow-up press release, the current distributors of Zonda's medical diagnostic testing product for Chlamydia are very happy with the HandiLab product. Given the increasing health threat posed by growing rates of Chlamydia infection, we believe that interest in a rapid detection technology for this disease will continue to be high.

We were also pleased to find several additional companies and technologies that we consider to be candidates for acquisition, licensing and/or distribution relationships. We expect to know more as we move forward with our due diligence and potentially negotiations with management of these candidates.

MEDICA introduced us to everything from innovative technologies that would still need to be developed into medical diagnostic products, to fully developed products that have already achieved U.S. regulatory approvals and are currently sold in international markets. We look forward to reporting any future progress with these candidates at the appropriate times.

One of the reasons that our MEDICA visit was so successful was the presence of a management representative from American Health Partners, who have signed on as our strategic partners to assist with the launch of medical diagnostic testing products in CLX's subsidiary operations. AHP's experience was invaluable at MEDICA as we sought to identify the best possible candidates for CLX.

I expect to maintain a consistent dialogue with CLX shareholders as we work with Zonda on the launch of its medical diagnostic testing products in new markets, including in the United States. I anticipate providing additional information on the status of Zonda to the public markets in the near term, and elaborating on our plans for this subsidiary and its products. I hope shareholders will continue to track our progress through press releases and this newsletter and will provide feedback whenever possible. We can be reached through our shareholder communications representatives by telephone at 951-677-8073 and by email at investors@clxinvestments.com. We look forward to hearing from you.

Regards,

Vera Leonard
Chief Executive Officer

Forward-Looking Statements

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

American Health Partners and Safis Solutions Contracted to Provide Services for Current and Future Subsidiary Technologies

(continued from page 1)

"AHP has a track record of assisting with the successful launch of new medical diagnostic testing products in the U.S. market, and we are pleased to have entered into this agreement to work with AHP on Zonda's Chlamydia product," stated Ms. Leonard. "As we review additional potential acquisition opportunities for CLX this week at MEDICA, the agreement with AHP takes on even greater significance. We expect that this relationship will be utilized for all future products that are acquired by CLX."

In addition to the AHP agreement, CLX announced that Safis Solutions, LLC has been engaged to provide ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.

Safis Solutions, an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners. Safis Solutions



has over 20 full-time staff, as well as partnerships with more than 60 other experts in their respective fields.

The immediate focus of Safis Solutions' work on behalf of CLX will be Zonda's rapid point of care test for Chlamydia. Safis Solutions will guide the development of a quality system that is compliant with the IVD Directive 98/79/EC and ISO 13485. This involves review and updating of all Standard Operating Procedures (SOPs) as they relate to manufacturing, procurement, management, quality assurance and contracting. In addition, Safis Solutions will function as Zonda's quality manager until such time as Zonda brings that function in house.

Safis Solutions will also design, implement and manage clinical trials that meet the requirements of U.S. and international regulatory bodies. Upon completion of the clinical trials, Safis Solutions will prepare and submit documents for FDA clearance, waived status under the Clinical Laboratory Improvement Act of 1988 (CLIA) and CE marking for sale of products in the countries of the European Union.

Gretchen Bowker, M.S., RAC, Director of Regulatory Affairs Services and Compliance Services for Safis Solutions, will oversee the Zonda project. Ms. Bowker has over 20 years of experience in life sciences product development in both start up and large pharmaceutical and device companies. She has successfully negotiated approvals/activations of U.S. and European market approvals. She also has extensive experience in building and overseeing a life science company's Quality System and programs. As a trained protein chemist, Bowker specializes in global Chemistry Manufacturing and

Control regulatory requirements for biotechnology products, such as proteins, peptides and cellular based therapies.

Ms. Leonard commented, "We are pleased to have Safis Solutions on board to provide ongoing consulting services for Zonda's rapid point of care test for Chlamydia, as well as any additional medical diagnostic testing products that are associated with CLX in the future.

"Safis Solutions is expected to provide support to Zonda's management team in the formulation of plans and decisions as they relate to quality and regulatory issues, and we believe that working with professionals with this depth of experience and expertise greatly augments Zonda's efforts to bring these unique and important products to the worldwide healthcare market," Ms. Leonard added.

CLX Completes Successful Attendance at MEDICA 2007

(continued from page 2)

CLX intends to acquire, license and distribute innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States. The company recently announced a professional services agreement with American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing in CLX subsidiary operations, including, but not limited to, the Zonda product lines. AHP (www.ahpartners.com) has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States.

A senior management representative from AHP accompanied Ms. Leonard to MEDICA to assist in the identification of potential suitable acquisition candidates, as well as those that may be licensed and/or targeted for distribution.

"AHP's experience was invaluable in identifying the best possible candidates, and I am pleased to report that several companies and technologies have already been targeted for additional due diligence and negotiations with management. The candidates ranged from innovative technologies that would still need to be developed into medical diagnostic products, to fully developed products that have already achieved U.S. regulatory approvals and are currently sold in international markets. This range is expected to allow CLX to develop a strategy under which it would have products in various stages of market readiness -- including near-term, mid-term and long-term development. We look forward to reporting to CLX shareholders our ongoing progress in each of these areas. At this point, we can say without reservation that the MEDICA visit was well worth the effort, and we expect to see identifiable results," Ms. Leonard said.